



O JAN 4 2005 2:17PM BMS PATENT DEPT

NO. 3608 P. 4

Attorney Docket No.: DIV of HA0721A (DIV IV)

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the United States Patent and Trademark Office, Official Fax (703) 746-4000 on the date shown below.

Tina Markee
Type or print name

Signature

January 4, 2005
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LLOYD ET AL.

EXAMINER: RAO, DEEPAK

APPLICATION NO: 10/823,987

Group Art Unit: 1624

FILED: April 14, 2004

FOR: POTASSIUM CHANNEL INHIBITORS AND METHOD

Assistant Commissioner for Patents
Washington, D.C. 20231
Box Issue Fee

AMENDMENT UNDER RULE 1.312

Commissioner:

OK
to
Enter

OK
2/3/05

Applicants request amendment of claim 18 (as renumbered by the Examiner's Amendment mailed October 4, 2004, to correct a non-substantive error therein. By way of this amendment, the definition of R³, which was rendered extraneous by a preceding restriction requirement, is removed. A full text of the claims, as amended to date in the prosecution and further amended by this pleading, is attached hereto.

The required filing fees are authorized to be charged, or any overpayment thereof credited to the Assignee's Deposit Account No. 19-3880.

Respectfully submitted,

Deanna L. Baxam
Attorney for Applicants
Reg. No. 45,266

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 262-4014
Date: January 4, 2005